These PS–dendrimers enabled targeted photodynamic therapy, reducing tumor size in a HER2-positive SKOV-3 xenograft model, highlighting their potential for apoptosis induction.181 Dhull et al. developed a generation 4 hydroxy PAMAM dendrimer (PD) conjugated with prostate-specific membrane antigen (PSMA) ligand (PD-CTT1298) for targeted prostate cancer therapy. Here, FOLH1 is linked to prostate carcinoma.